Molecular structure of Dabigatran etexilate, CAS Number: 211915-06-9
Dabigatran etexilate (CAS 211915-06-9)
See product citations (2)
Application:
Dabigatran etexilate is an anticoagulant from the class of direct thrombin inhibitors
CAS Number:
211915-06-9
Purity:
≥98%
Molecular Weight:
627.73
Molecular Formula:
C34H41N7O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Dabigatran etexilate is an inhibitor of Prothrombin. It is metabolized into the bioactive compound dabigatran. Dabigatran etexilate metabolism occurs through hydrolysis. This process unveils dabigatran, which exhibits its biochemical activity by directly inhibiting thrombin. Thrombin is a enzyme in the coagulation cascade. Understanding the mechanism by which dabigatran etexilate is activated and inhibits its target enzyme offers insights into enzyme inhibition and the regulation of physiological processes. This knowledge contributes to the field of biochemistry by illustrating how specific molecular modifications can alter a compound′s ability to interact with biological systems, thereby influencing its activation and mechanism of action at the molecular level.
Dabigatran etexilate (CAS 211915-06-9) References
- Plasma osmolality, iodine concentration and urographic images following high and low osmolar contrast media. | Todd, AW., et al. 1991. Clin Radiol. 43: 331-6. PMID: 2036759
- Dabigatran etexilate: a new thrombin inhibitor. | Verma, AK. 2010. Med J Aust. 192: 407-12. PMID: 20367591
- New options with dabigatran etexilate in anticoagulant therapy. | Maegdefessel, L., et al. 2010. Vasc Health Risk Manag. 6: 339-49. PMID: 20531953
- Drug and dietary interactions of the new and emerging oral anticoagulants. | Walenga, JM. and Adiguzel, C. 2010. Int J Clin Pract. 64: 956-67. PMID: 20584229
- Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. | Garnock-Jones, KP. 2011. Am J Cardiovasc Drugs. 11: 57-72. PMID: 21265583
- Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry. | Tsivgoulis, G., et al. 2014. Ther Adv Neurol Disord. 7: 155-61. PMID: 24790645
- The effects of dabigatran etexilate on fracture healing in rats: An experimental study. | Kerimoglu, S., et al. 2015. Indian J Orthop. 49: 357-60. PMID: 26015639
- Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice. | Preusch, MR., et al. 2015. Drug Des Devel Ther. 9: 5203-11. PMID: 26392754
- Pharmacogenetics of dabigatran etexilate interindividual variability. | Dimatteo, C., et al. 2016. Thromb Res. 144: 1-5. PMID: 27261537
- Investigation on Dabigatran Etexilate and Worsening of Renal Function in Patients with Atrial fibrillation: The IDEA Study. | Molteni, M., et al. 2019. Clin Drug Investig. 39: 355-362. PMID: 30697670
- Inhibitory effects of dabigatran etexilate, a direct thrombin inhibitor, on osteoclasts and osteoblasts. | Rocha, AL., et al. 2020. Thromb Res. 186: 45-53. PMID: 31883999
- A chemometric comparison of different models in fluorescence analysis of dabigatran etexilate and dabigatran. | Wang, T., et al. 2021. Spectrochim Acta A Mol Biomol Spectrosc. 246: 118988. PMID: 33065449
- Comparison of the efficacy of rivaroxaban and dabigatran etexilate in preventing venous thrombosis after arthroplasty: A protocol of randomized controlled trial. | Song, R., et al. 2021. Medicine (Baltimore). 100: e23814. PMID: 33429741
- Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions. | Lang, J., et al. 2021. Eur J Pharm Sci. 165: 105932. PMID: 34260894
- Dabigatran Etexilate Induces Cytotoxicity in Rat Gastric Epithelial Cell Line via Mitochondrial Reactive Oxygen Species Production. | Kurokawa, H., et al. 2021. Cells. 10: PMID: 34685491
Inhibitor of:
Prothrombin.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dabigatran etexilate, 10 mg | sc-351724 | 10 mg | $163.00 |